Диссертация (1174284), страница 19
Текст из файла (страница 19)
– 2017. – N 66. –P. 153–194.13057.EASL recommendations on treatment of hepatitis C 2018 / EASL // J.Hepatol. – 2018. – N 69 (2). –P. 461–511.58.Egli, A. The impact of the interferon-lambda family on the innate andadaptive immune response to viral infections / A. Egli, D. M. Santer, D. O'Shea [et al.] //Emerg. Microbes Infect. – 2014 Jul.
– N 3(7). – P. e51..59.El-Kamary, S. S. Prevalence of hepatitis C virus infection in urban children/ S. S. El-Kamary, J. R. Serwint, A. Joffe [et al.] // J. Pediatr. – 2003. – N 143 (1). – P. 54–59..60.El-Sayed, M. Global estimate of ХГСinfection in the pediatric andadolescent population / M. El-Sayed, H. Razavi // J. Hepatol. – 2015. – N 62. – P. 831–832.61.Esmat, G.
Risk factors for hepatitis C virus acquisition and predictors ofpersistence among Egyptian children / G. Esmat, M. Hashem, M. El-Raziky [et al.]// Liver Int. – 2012. – N 32. – P. 449–456.62.Esteban, J. L. Hepatitis C: molecular biology, pathogenesis, epidemiology,clinical Features and Prevention / J. L. Еsteban, J. Genesca, H. J. Alter // Progresses inLiver Diseases.
– 1992. – N 10. – P. 253–282.63.European Association for the Study of the Liver. EASL Clinical PracticeGuidelines: management of hepatitis C virus infection // J. Hepatol. – 2011. – N 55. – P.245–264.64.European Pediatric Hepatitis C Virus Network. A significant sex – but notelective Cesarean section – effect on mother-to-child transmission of ХГС infection // J.Infect. Dis. – 2005 Dec 1. – N 192 (11).
– P. 1872–1879.65.Farinati F, Cardin R, Bortolami M, Guido M, Rugge M.Oxidative damage,pro-inflammatory cytokines, TGF-a and c-myc in chronic ХГС -related hepatitis andcirrhosis // World J. Gastroenterol. 2006. V.12. P. 2065–2069.66.Fried, M. W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virusinfection / M. W. Fried, M. L. Shiffman, K. R. Reddy [et al.] // N. Engl. J. Med. – 2002.– N 347. – P. 975–982.
.13167.Gale, M. Jr. Evasion of intracellular host defence by hepatitis C virus / M.Gale Jr ., E. M. Foy // Nature. – 2005. – N 436. – P. 939–945.68.Ge, D. Genetic variation in IL28B predicts hepatitis C treatment-inducedviral clearance / D. Ge, J. Fellay, A. J.Thompson [et al.] // Nature. – 2009. – N 461.
– P.399–401.69.Ghany, M. G. Diagnosis, management, and treatment of hepatitis C: anupdate / M. G. Ghany, D. B. Strader, D. L. Thomas [et al.] // Hepatology. – 2009. – N 49.– P. 1335–1374.70.Goldstein N. S. Serum alpha-fetoprotein levels in patients with chronichepatitis C : relationships with serum alanine aminotransferase values, histologic activityindex, and hepatocyte MIB-1 scores / N. S. Goldstein, D. E. Blue, R. Hankin [et al.] //Am. J. Clin. Pathol. – 1999. – N 6 (111). – Р. 811−816.71.Gonzales-Peralta, R.
Hepatocellular carcinoma in two young adolescentswith chronic hepatitis / R. Gonzales-Peralta, M. R. Langham Jr., J. M. Andres [et al.] //C. J. Pediatr. Gastroenterol. Nutr. – 2009 May. – N 48 (5). – P. 630–635.72.Gonzalez, S. A. IL-28B As a Predictor of Sustained Virologic Response inPatients with Chronic Hepatitis C Virus Infection / S. A. Gonzalez, E. B.
Keeffe //Gastroenterol Hepatol (N Y). – 2011 Jun . – N 7 (6). – P. 366–373.73.Gower, E. Global epidemiology and genotype distribution of the hepatitis Cvirus infection / E. Gower, C. Estes, S. Blach [et al.] // J. Hepatol. – 2014. – N 61. –P. 45–57.74.Haber, B.
Long-term follow-up of children treated with peginterferon andribavirin for hepatitis c virus infection / B. Haber, E. Alonso, A. Pedreira [et al.] // J.Pediatr. Gastroenterol. Nutr. – 2017. – N 64. – P. 89–94.75.Hadziyannis, S. J. Peginterferon-alpha2a and ribavirin combination therapyin chronic hepatitis C: a randomized study of treatment duration and ribavirin dose / S. J.Hadziyannis, H. Jr. Sette, T. R. Morgan [et al.] // Ann.
Intern. Med. // 2004. – N 140. –P. 346–355.13276.Halfon, P. IL-28B polymorphism and hepatitis C: impact on viral clearance– prolonged, spontaneous and after treatment with antiviral drugs / P. Halfon, P. Cacoub// Rev. Med. Interne. – 2011. – N 32 (5). – P. 271–274.77.Hu, K. Q. Clinical significance of elevated alpha (fetoprotein (AFP) inpatients with chronic hepatitis C, but not hepatocellular carcinoma / K. Q. Hu, N. L.Kyulo, N. Lim // Am.
J. Gastroenterology. – 2004. – N 5 (99). – P. 860–865.78.Hutyrova B., Pantelidis P., Drabek J., Zůrková M., Kolek V., Lenhart K.,Welsh K.I., Du Bois R.M., Petrek M.. Interleukin-1 gene cluster polymorphisms insarcoidosis and idiopathic pulmonary fibrosis // Am J. Respir Crit Care Med. 2002.V.165. P.148– 151.79.Ijaz, B. Association of laboratory parameters with viral factors in patientswith hepatitis C / B. Ijaz, A. Waqar, T. Fouzia [et al.] // Virology Journal. – 2011. – N 361(8).
– P. 1–9.80.Indolfi, G. Perinatal transmission of hepatitis C virus / G. Indolfi, C. Azzari,M. Resti // J. Pediatr. – 2013. – N 163. – P. 1549–1552.Bortolotti, F. Long-term courseof chronic hepatitis C in children: from viral clearance to end-stage liver disease / F.Bortolotti, G. Verucchi, C. Cammà [et al.] // Gastroenterology. – 2013. – V. 134 (7). – Р.1900–1907.81.Indolfi, G. Treatment of chronic hepatitis c virus infection in children: aposition paper by the hepatology committee of european society of pediatricgastroenterology, hepatology and nutrition / G. Indolfi, L.
Hierro, A. Dezsofi [et al.] //Journal of pediatric gastroenterology and nutrition. – 2018. – N 66 (3) – P. 505–515.82.Jara, P. Efficacy and safety of peginterferon-alpha2b and ribavirincombination therapy in childrenwith chronic hepatitis C infection / P. Jara, L. Hierro, A.de la Vega A [et al.] // Pediatr. Infect. Dis. J. – 2008. – N 27. – P. 142–148.83.Jara, P. Treatment of hepatitis C in children / P. Jara, L.
Hierro // Expert Rev.Gastroenterol. Hepatol. – 2010. – N 4 (1). – P. 51–6184.Jia, Hu. Treatment of hepatitis C in children: a systematic review / Hu Jia,K. Doucette, L. Hartling [et al.] // PLoS One. – 2010. – N 5 (7). – P. e11542.13385.Jonas, M. M. Peginterferon for Chronic Hepatitis C in Children affectsGrowth and Body Composition: Results from the Pediatric Study of Hepatitis C (PEDSC) Trial./ M. M. Jonas, W. Balistreri / Hepatology.
– 2012. – N 56 (2). – S. 523–531.Hepatology. 2012 Aug; 56(2): 523–531.86.Jonas, M. M. Long-term growth outcomes in children treated for chronichepatitis C / M. M. Jonas, K. B. Schwarz, R. Gonzalez-Peralta [et al.] // J. Pediatr. – 2014.– N 165. – P. 1252–1254.87.Juki, N. Relation of disease activity during chronic hepatitis С infection tocomplexity of hyper-variable region 1 quasispecies / N. Juki, N. Hayashi, T.
Moribe [etal.] // Hepatology. – 1997. – N 25. – P. 439–444.88.Kalinina, O. A Natural intergenotypic recombinant of hepatitis C virusidentified in St. Petersburg / O. Kalinina, H. Norder, S. Mukomolov [et al.] // Society. –2002. – N 76. –P. 4034–4043.89.Kamal, S. M. Hepatitis C genotype 4: What we know and what we don’t yetknow / S. M. Kamal, I.
A. Nasser // Hepatology. – 2008. – N 47. – P. 1371–1383.90.Kelly, C. Interferon lambdas: the next cytokine storm / C. Kelly, P.Klenerman, E. Barnes // Gut. – 2011. – Vol. 60. – P. 1284-1293.91.Kelly, D. A. Durability of sustained response shown in paediatric patientswith chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin / D. A.Kelly, B. Haber, R. P.
Gonzalez-Peralta [et al.] // J. Viral. Hepat. – 2012. – N 19. – P.263–270..92.Kershenobich, D. Trends and projections of hepatitis C virus epidemiologyin Latin America / D. Kershenobich, H. A. Razavi, J. F. Sánchez-Avila [et al.] // LiverInt. – 2011. – N 31 (Suppl. 2). – P. 18–29.93.Kobayashi, M. Natural history of compensated cirrhosis in the Child-Pughclass A compared between 490 patients with hepatitis C and 167 with B virus infections/ M. Kobayashi, K. Ikeda, T. Hosaka [et al.] // J. Med. Virol. – 2006.
– N 4 (78). –P. 459−465.13494.Kolykhalov, A. A. Identification of a higly conserved seoquence element atthe 3” terminus of hepatitis C virus / A. A. Kolykhalov, S. M. Feinstone, C. M. Rice // J.Virol. – 1996. – V. 70. – P. 3363–3371.95.Lee, A. Chronic Hepatitis C Infection in Children: current treatment and newtherapies / A. Lee, J.
Rajanayagam, M. Abdel-Hady // J. Clin. Transl. Hepatol. – 2015. –N 3 (1). – P. 36–41.96.Li, C. Diagnostic accuracy of desgammacarboxy prothrombin versus αfetoprotein for hepatocellular carcinoma: a systematic review / C. Li, Z. Zhang, P. Zhang[et al.] // Hepatol. Res. – 2014. – N 44. –P. 11–25.97.Lingala, S. Natural history of hepatitis С.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
